The present invention is directed to treatment of cervical dystonia using a modified BoNT/A, including a modified botulinum neurotoxin A (BoNT/A) for use in treating cervical dystonia, wherein the modified BoNT/A is administered by intramuscular injection to an affected neck muscle of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 750 pg to 17,000 pg of modified BoNT/A, wherein at least a single unit dose is administered to the affected neck muscle, wherein the total dose administered during the treatment is up to 170,000 pg of modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are associated methods, uses, unit dosage forms, and kits.
The present invention relates to the treatment of autonomic disorders with a clostridial neurotoxin comprising a HCC domain from a BoNT/B, BoNT/D, BoNT/D-C, BoNT/F or BoNT/G, wherein the dose of the clostridial neurotoxin to be administered to the patient is equivalent to or lower than the dose of BoNT/A that would be used to treat the same autonomic disorder.
The present invention provides a clostridial neurotoxin for use in a method of suppressing visceral pain in a patient. The method comprises: (a) identifying an organ in the patient that is causing said visceral pain; (b) mapping said organ to a specific dermatome nerve according to the following instructions, thereby matching said organ to one or more specifically designated dermatome nerve(s): urinary bladder maps to the T11, T12, L1, S1, S2, S3 and/or S4 dermatome nerve(s); fallopian tube(s) maps to the T11 dermatome nerve(s); uterus maps to the T12 and/or L1 dermatome nerve(s); cervix maps to the S2, S3 10 and/or S4 dermatome nerve(s); stomach maps to the T8, T9 and/or T10 dermatome nerve(s); liver maps to the T8, T9, T10 and/or T11 dermatome nerve(s); gall bladder maps to the T8, T9, T10 and/or T11 dermatome nerve(s); pancreas maps to the T7, T8, T9, T10, T11 and/or T12 dermatome nerve(s); small intestine maps to the T10, T11 and/or T12 dermatome nerve(s); colon maps to the T11, S1, S2, S3 and/or S4 dermatome nerve(s); kidney maps to the T10, T11, T12 and/or L1 dermatome nerve(s); ureter maps to the T11, T12 and/or L1 dermatome nerve(s); ovary maps to the T11 dermatome nerve(s); testes maps to the T10, T11, L1, L2, S1, S2, S3 and/or S4 dermatome nerve(s); epididymis maps to the T10, T11, L1, L2, S1, S2, S3 and/or S4 dermatome nerve(s); and (c) administering a therapeutically effective amount of a clostridial neurotoxin at a site proximal to said one or more specifically designated dermatome nerve(s), wherein following administration of said clostridial neurotoxin to the patient, the clostridial neurotoxin is transported via retrograde axonal transport to the spinal cord where it binds sensory afferent nerve cells, enters said cells by receptor-mediated endocytosis and suppresses neurotransmitter release therefrom, thereby suppressing said visceral pain.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
4.
CATALYTICALLY INACTIVE CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PAIN & INFLAMMATORY DISORDERS
The present invention is directed to a polypeptide for use in treating pain or an inflammatory disorder, wherein the polypeptide comprises a clostridial neurotoxin light-chain (L-chain), a clostridial neurotoxin translocation domain (HN domain) and/or a clostridial neurotoxin receptor binding domain (Hc domain), wherein when the polypeptide comprises a clostridial neurotoxin L-chain, the L-chain is catalytically inactive. Also provided are corresponding methods of treatment and uses.
C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmacy services; online retail store services featuring pharmaceutical products; online retail pharmacy services for the ordering, purchase, and delivery of pharmaceutical products; pharmaceutical services, namely, processing prescription orders Platform as a service featuring computer software to permit users to identify, request and receive pharmaceutical products Providing information relating to therapeutic properties of pharmaceuticals
6.
TREATMENT OF A HEADACHE DISORDER WITH A BOTULINUM NEUROTOXIN A
Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
8.
Methods For Treating Pancreatic Cancer Using Combination Therapies
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
The present invention is directed to a modified clostridial neurotoxin comprising a botulinum neurotoxin A (BoNT/A) Hcc domain, wherein the Hcc domain comprises a modification of methionine 1144 (MI 144), and wherein the modification increases oxidative resistance of the modified clostridial neurotoxin when compared to an otherwise identical clostridial neurotoxin lacking the modification. Also provided are (inter alia) corresponding methods for producing the same, methods for selecting oxidation resistant clostridial neurotoxins, nucleic acids encoding the same, and therapeutic uses of said modified clostridial neurotoxins.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting clinical trials for pharmaceutical products for others
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
13.
İXCELLENCE NETWORK Centers of excellence for HCP education
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Downloadable electronic publications, podcasts and videos in
the field of botulinum toxin. Printed matter, brochures, leaflets, printed teaching
materials in the field of botulinum toxin. Education and training services for healthcare
professionals; arranging and conducting of colloquiums,
conferences, congresses, seminars, symposiums; providing
online publications; providing non-downloadable on-line
videos and production of podcasts. Providing medical information to healthcare professionals,
including information provided via a website. Online social networking services in the field of botulinum
toxin.
14.
Clostridial Neurotoxins Comprising an Exogenous Activation Loop
The present invention relates to a method for proteolytically processing a single-chain clostridial neurotoxin into a corresponding di-chain clostridial neurotoxin, the method comprising: providing a single-chain clostridial neurotoxin; and contacting the single-chain clostridial neurotoxin with furin; wherein the single-chain clostridial neurotoxin has an activation loop comprising or consisting of the polypeptide sequence Arg-Xaa-Xaa-Arg; and wherein furin hydrolyses a peptide bond of the activation loop thereby producing a di-chain clostridial neurotoxin. The invention also relates to engineered clostridial neurotoxins and methods for manufacturing the same, as well as related pharmaceutical compositions, nucleotide sequences, and therapeutic and cosmetic uses.
The present invention relates to clostridial neurotoxins engineered to comprise an endosomal protease cleavage site within the activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The invention also relates to methods for manufacturing the same, as well as related pharmaceutical compositions, nucleotide sequences, and therapeutic and cosmetic uses. The invention further relates to a method for proteolytically processing said single-chain clostridial neurotoxins into a corresponding di- chain clostridial neurotoxin.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
16.
CLOSTRIDIAL NEUROTOXINS COMPRISING AN ACTIVATING EXOGENOUS PROTEASE CLEAVAGE SITE
The present invention relates to clostridial neurotoxins engineered to comprise an exogenous protease cleavage site within a modified activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The invention also relates to methods for manufacturing the same, as well as related pharmaceutical compositions, nucleotide 10 sequences, and therapeutic and cosmetic uses. The invention further relates to a method for proteolytically processing said single-chain clostridial neurotoxins into a corresponding di- chain clostridial neurotoxin.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
17.
CLOSTRIDIAL NEUROTOXIN FOR USE IN A TREATMENT OF BLADDER PAIN SYNDROME
The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volume of solution comprising the clostridial neurotoxin present within the bladder, thereby applying a mechanical force against the inner surface of the urothelial layer; and maintaining said volume of solution comprising the clostridial neurotoxin present within the bladder at a volume that does not give rise to patient micturition and for a duration of at least 30 minutes, thereby allowing the clostridial neurotoxin to diffuse across the urothelial layer and into the lamina propria, where the clostridial neurotoxin binds to primary sensory afferent nerve fibres, suppresses secretion of neurotransmitters therefrom, and alleviates bladder pain.
The present invention is directed to cell-free methods, such as those for determining the clostridial neurotoxin activity of a composition, determining whether or not a composition comprises clostridial neurotoxin polypeptides, and/or determining whether or not clostridial neurotoxin polypeptides or portions thereof comprised in a composition comprise an activity-altering property. The invention is also directed to an isolated capture substrate for a clostridial neurotoxin, use of the same, therapeutic or cosmetic clostridial neurotoxin compositions, and methods for producing the same.
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The present invention provides a clostridial neurotoxin for use in a method of treating a brain disorder in a patient by promoting a neuroimmune response.
The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 8/39 - Dérivés contenant 2 à 10 groupes oxyalkylène
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
(1) Downloadable electronic publications, podcasts and videos in the field of botulinum toxin.
(2) Printed matter, brochures, leaflets, printed teaching materials in the field of botulinum toxin. (1) Education and training services for healthcare professionals; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums; providing online publications; providing non-downloadable on-line videos and production of podcasts.
(2) Providing medical information to healthcare professionals, including information provided via a website.
(3) Online social networking services in the field of botulinum toxin.
22.
IXCELLENCE NETWORK CENTERS OF EXCELLENCE FOR HCP EDUCATION
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Downloadable electronic publications in the nature of podcasts in the field of botulinum toxin Printed matter, namely, hand-outs, brochures, and printed teaching materials all in the field of botulinum toxin Education and training services for healthcare professionals, namely, conducting providing live and on-line classes, colloquiums, conferences, congresses, seminars, symposiums and workshops in the field of botulinum toxin; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums in the field of botulinum toxin; providing online non-downloadable publications in the nature of podcasts, articles and brochures in the field of botulinum toxin Providing medical information to healthcare professionals, including medical information provided via a website Online social networking services in the field of botulinum toxin.
The present invention relates to the treatment of skin conditions with neurotoxins, and non-therapeutic uses for cosmetic treatment of the skin. Administration of the neurotoxin induces secretion of one or more sebaceous lipid(s) selected from a squalene, a fatty acid, a cholesterol, and a wax ester to an epidermal layer of skin.
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Downloadable electronic publications, podcasts and videos in the field of botulinum toxin. Printed matter, brochures, leaflets, printed teaching materials in the field of botulinum toxin. Education and training services for healthcare professionals; Arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums; Providing online publications; Providing nondownloadable videos and podcasts. Providing medical information to healthcare professionals, including information provided via a website. Online social networking services in the field of botulinum toxin.
The present invention provides a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of greater than 1754 pg (e.g. greater than 1800 pg) of modified BoNT/A per site, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines, and up to three sites of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 88,000 pg, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN domain), and a BoNT/B receptor binding domain (HC domain).
The present invention is directed inter alia to a modified botulinum neurotoxin A (BoNT/A) for use in treating cervical dystonia, wherein the modified BoNT/A is administered by intramuscular injection to an affected neck muscle of a subject, wherein the modified BoNT/A is administered by way of a unit dose of greater than 17,000 pg of modified BoNT/A, wherein at least a single unit dose is administered to the affected neck muscle, wherein the total dose administered during the treatment is up to 400,000 pg of modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are corresponding methods, uses, unit dosage forms, and kits.
The present invention is directed to a modified botulinum neurotoxin A (BoNT/A) for use in treating a facial dystonia, including blepharospasm and hemifacial spasm, wherein the unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the modified BoNT/A is administered by intramuscular injection to an affected muscle of a subject, wherein the total dose administered during the treatment is greater than 24,000 pg and up to 82,500 pg (e.g. up to 75,000 pg) of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN), and a BoNT/B receptor binding domain (HC domain).
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
The invention is directed to treatment of limb spasticity using a modified botulinum neurotoxin A (BoNT/A) comprising a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are unit dosage forms of said modified BoNT/A and corresponding kits.
The present invention relates to a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of Units to 41 Units of modified BoNT/A per site and wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines; and up to three sites at the external part of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 574 Units, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 15 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: i. substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; ii. substitution of an acidic surface exposed amino acid residue with an uncharged amino acid residue; iii. substitution of an uncharged surface exposed amino acid residue with a basic amino acid residue; iv. insertion of a basic amino acid residue; and v. deletion of an acidic surface exposed amino acid residue. Also provided are corresponding methods of treatment and uses, as well as unit dosage forms, and kits.
The present invention is directed inter alia to a modified botulinum neurotoxin A (BoNT/A) for use in treating cervical dystonia, wherein the modified BoNT/A is administered by intramuscular injection to an affected neck muscle of a subject, wherein the modified BoNT/A is administered by way of a unit dose of greater than 17,000 pg of modified BoNT/A, wherein at least a single unit dose is administered to the affected neck muscle, wherein the total dose administered during the treatment is up to 400,000 pg of modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are corresponding methods, uses, unit dosage forms, and kits.
The present invention is directed to a modified botulinum neurotoxin A (BoNT/A) for use in treating a facial dystonia, including blepharospasm and hemifacial spasm, wherein the unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the modified BoNT/A is administered by intramuscular injection to an affected muscle of a subject, wherein the total dose administered during the treatment is greater than 24,000 pg and up to 82,500 pg (e.g. up to 75,000 pg) of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN), and a BoNT/B receptor binding domain (HC domain).
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
The invention is directed to treatment of limb spasticity using a modified botulinum neurotoxin A (BoNT/A) comprising a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are unit dosage forms of said modified BoNT/A and corresponding kits.
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Downloadable electronic publications in the field of
botulinum toxin. Printed matter, brochures, printed teaching materials in the
field of botulinum toxin. Education and training services for healthcare
professionals; arranging and conducting of colloquiums,
conferences, congresses, seminars, symposiums; providing
online publications. Providing medical information to healthcare professionals,
including information provided via a website. Online social networking services in the field of botulinum
toxin.
The present invention provides a modified botulinum neurotoxin A (BoNT/A) L-chain protease that demonstrates enhanced cleaveage of human SNAP-23 (hSNAP-23) relative to unmodified (wild-type) BoNT/A L-chain protease, together with the use thereof for cleaving hSNAP-23.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
36.
IXCELLENCE SHARING EXPERTISE, IMPROVING PATIENT CARE
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
(1) Downloadable electronic publications in the field of botulinum toxin.
(2) Printed matter, brochures, printed teaching materials in the field of botulinum toxin. (1) Education and training services for healthcare professionals; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums; providing online publications.
(2) Providing medical information to healthcare professionals, including information provided via a website.
(3) Online social networking services in the field of botulinum toxin.
37.
IXCELLENCE SHARING EXPERTISE, IMPROVING PATIENT CARE
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Downloadable electronic publications in the nature of podcasts and audio files in the field of botulinum toxin Printed matter, namely, hand-outs, brochures, and printed teaching materials all in the field of botulinum toxin Education and training services for healthcare professionals, namely, conducting and providing live and on-line classes, colloquiums, conferences, congresses, seminars, symposiums and workshops in the field of botulinum toxin; arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums in the field of botulinum toxin; providing online non-downloadable publications in the nature of podcasts, audio files, articles and brochures in the field of botulinum toxin Providing medical information to healthcare professionals, including medical information provided via a website Online social networking services in the field of botulinum toxin
38.
İXCELLENCE Sharing expertise, improving patient care
09 - Appareils et instruments scientifiques et électriques
16 - Papier, carton et produits en ces matières
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Downloadable electronic publications in the field of botulinum toxin. Printed matter, brochures, printed teaching materials in the field of botulinum toxin. Education and training services for healthcare professionals; Arranging and conducting of colloquiums, conferences, congresses, seminars, symposiums; Providing online publications. Providing medical information to healthcare professionals, including information provided via a website. Online social networking services in the field of botulinum toxin.
The present invention relates to a modified botulinum neurotoxin A (BoNT/A) for use in treating limb spasticity or paediatric limb spasticity, wherein the modified BoNT/A is administered by intramuscular injection to a plurality of affected muscles of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 53 Units to 948 Units or 26.5 Units to 474 Units of modified BoNT/A at the plurality of affected muscles.
There is provided a method of controlling operation of a fed batch process in a bioreactor vessel, comprising transitioning from a batch phase to a production phase in dependence on a relationship between an oxygen supply parameter O and a dissolved oxygen value DO.
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
C12M 1/06 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'introduction de gaz avec agitateur, p. ex. avec agitateur à turbine
41.
TREATMENT OF MODERATE TO VERY SEVERE GLABELLAR LINES AND LATERAL CANTHAL LINES
The present invention relates to a clostridial neurotoxin for use in treating post-operative surgical pain in a patient, said method comprising administering to a patient a clostridial neurotoxin more than 5 days prior to surgery and wherein the clostridial neurotoxin is administered: i) intradermally; or ii) intrathecally.
The present invention relates to a clostridial neurotoxin for use in treating post-operative surgical pain in a patient, said method comprising administering to a patient a clostridial neurotoxin more than 5 days prior to surgery and wherein the clostridial neurotoxin is administered: i) intradermally; or ii) intrathecally.
Also provided are corresponding methods of treatment and administration dosages of a clostridial neurotoxin.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
The present invention is directed inter alia to the treatment of pain. For example, there is provided a chimeric clostridial neurotoxin for use in treating pain by inhibiting release of a pain mediator from a neuron comprising an A? nerve fiber or a C nerve fiber, wherein the chimeric clostridial neurotoxin binds to the neuron comprising the A? nerve fiber or the C nerve fiber, respectively, and wherein the chimeric clostridial neurotoxin comprises a botulinum neurotoxin A (BoNT/A) light-chain and translocation domain (HN domain), and a BoNT/B receptor binding domain (He domain). Also provided are methods, uses, kits, and unit dosage forms.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
The present invention provides a clostridial neurotoxin for use in a method of suppressing visceral pain in a patient. The method comprises: (a) identifying an organ in the patient that is causing said visceral pain; (b) mapping said organ to a specific dermatome nerve according to the following instructions, thereby matching said organ to one or more specifically designated dermatome nerve(s): urinary bladder maps to the T11, T12, L1, S1, S2, S3 and/ or S4 dermatome nerve(s); fallopian tube(s) maps to the T11 dermatome nerve(s); uterus maps to the T12 and/ or L1 dermatome nerve(s); cervix maps to the S2, S3 10 and/ or S4 dermatome nerve(s); stomach maps to the T8, T9 and/ or T10 dermatome nerve(s); liver maps to the T8, T9, T10 and/ or T11 dermatome nerve(s); gall bladder maps to the T8, T9, T10 and/ or T11 dermatome nerve(s); pancreas maps to the T7, T8, T9, T10, T11 and/ or T12 dermatome nerve(s); small intestine maps to the T10, T11 and/ or T12 dermatome nerve(s); colon maps to the T11, S1, S2, S3 and/ or S4 dermatome nerve(s);kidney maps to the T10, T11, T12 and/ or L1 dermatome nerve(s); ureter maps to the T11, T12 and/ or L1 dermatome nerve(s); ovary maps to the T11 dermatome nerve(s); testes maps to the T10, T11, L1, L2, S1, S2, S3 and/ or S4 dermatome nerve(s); epididymis maps to the T10, T11, L1, L2, S1, S2, S3 and/ or S4 dermatome nerve(s); and (c) administering a therapeutically effective amount of a clostridial neurotoxin at a site proximal to said one or more specifically designated dermatome nerve(s), wherein following administration of said clostridial neurotoxin to the patient, the clostridial neurotoxin is transported via retrograde axonal transport to the spinal cord where it binds sensory afferent nerve cells, enters said cells by receptor-mediated endocytosis and suppresses neurotransmitter release therefrom, thereby suppressing said visceral pain.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p. ex. enzymes pancréatiques
A61P 13/02 - Médicaments pour le traitement des troubles du système urinaire de l'urine ou des voies urinaires, p. ex. acidificateurs d'urine
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/04 - Analgésiques centraux, p. ex. opioïdes
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
49.
MODIFIED BONT/A FOR USE IN THE TREATMENT OF A DISORDER AFFECTING AN EYELID MUSCLE OF A SUBJECT
The present invention is directed to a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN), and a BoNT/B receptor binding domain (HC domain).
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
50.
MODIFIED BONT/A FOR USE IN THE TREATMENT OF A DISORDER AFFECTING AN EYELID MUSCLE OF A SUBJECT
The present invention is directed to a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN), and a BoNT/B receptor binding domain (HC domain).
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61P 21/02 - Relaxants musculaires, p. ex. pour la tétanie ou les crampes
51.
MODIFIED BONT/A FOR USE IN THE TREATMENT OF CERVICAL DYSTONIA
The present invention is directed to treatment of cervical dystonia using a modified BoNT/A, including a modified botulinum neurotoxin A (BoNT/A) for use in treating cervical dystonia, wherein the modified BoNT/A is administered by intramuscular injection to an affected neck muscle of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 750 pg to 17,000 pg of modified BoNT/A, wherein at least a single unit dose is administered to the affected neck muscle, wherein the total dose administered during the treatment is up to 170,000 pg of modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light- chain and translocation domain, and a BoNT/B receptor binding domain (HC domain). Also provided are associated methods, uses, unit dosage forms, and kits.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
52.
Methods For Treating Pancreatic Cancer Using Combination Therapies
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
53.
MODIFIED BONT/A FOR USE IN THE TREATMENT OF CERVICAL DYSTONIA
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/166 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p. ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/416 - 1,2-Diazoles condensés avec des systèmes carbocycliques, p. ex. indazole
A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
55.
Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and Oxaliplatin
Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/475 - QuinoléinesIsoquinoléines ayant un cycle indole, p. ex. yohimbine, réserpine, strychnine, vinblastine
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
The present invention is directed to a polypeptide for use in promoting neuronal growth or neuronal repair to treat a neurological disorder in a subject, wherein the polypeptide comprises: a clostridial neurotoxin light chain (L-chain) or fragment thereof; and/or a fragment of a clostridial neurotoxin heavy chain (H-chain). Additional polypeptides for use in promoting neuronal growth or neuronal repair to treat a neurological disorder in a subject are also provided, as are corresponding methods and uses.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present technology relates to commercial-scale methods for purifying botulinum toxin compositions obtained from cell cultures. Purification methods according to the present disclosure are based on a series of filtration and chromatographic separation steps that produce a high-purity botulinum toxin composition, which comprises botulinum toxin protein molecules (˜150 kDa) in solution, which is free, essentially free, or substantially free of botulinum toxin complexes and animal products, and without precipitating or lyophilizing botulinum toxin protein molecules. The purification method according to the present disclosure uses no precipitation, lyophilization, or centrifugation steps, permitting production of highly pure, highly active, free botulinum toxin protein molecules (˜150 kDa) in solution, without the need for reconstitution by the end user.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
The present disclosure relates generally to the field of producing botulinum toxin. More specifically, the present disclosure relates to a method for producing botulinum toxin in a culture medium free or substantially free of animal product. The present disclosure also relates to the culture medium for producing botulinum toxin that is free or substantially free of animal product.
INSTITUTE OF MOLECULAR AND CELL BIOLOGY, BIOMEDICAL SCIENCES INSTITUTES (Singapour)
Inventeur(s)
Foster, Keith
Beard, Matthew
Yeo, Jeremy Changyu
Bard, Frederic Andre Jean
Tay, Pei Ling Felicia
Abrégé
The present invention is directed to a method for identifying a gene that regulates clostridial neurotoxin activity, the method comprising: a. providing a sample of human neuronal cells expressing a polypeptide that comprises a C-terminal detectable label, wherein the polypeptide is cleavable by a clostridial neurotoxin; b. altering expression of a target gene of the cells; c. contacting the cells with the clostridial neurotoxin; d. measuring an amount of C-terminal detectable label, thereby quantifying clostridial neurotoxin activity; and e. identifying the target gene as a regulator of clostridial neurotoxin activity when the quantified clostridial neurotoxin activity is different to the quantified clostridial neurotoxin activity when expression of the target gene is unaltered; or f. identifying that the target gene is not a regulator of clostridial neurotoxin activity when the quantified clostridial neurotoxin activity is equivalent to the quantified clostridial neurotoxin activity when expression of the target gene is unaltered. Also provided are related methods for identifying an agent that regulates clostridial neurotoxin activity, as well as human neuronal cells, nucleotides, vectors, polypeptides, kits, and compositions suitable for use in the methods of the invention.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention is directed to a polypeptide for use in treating pain or an inflammatory disorder, wherein the polypeptide comprises a clostridial neurotoxin light-chain (L-chain), a clostridial neurotoxin translocation domain (HN domain) and/or a clostridial neurotoxin receptor binding domain (HC domain), wherein when the polypeptide comprises a clostridial neurotoxin L-chain, the L-chain is catalytically inactive. Also provided are corresponding methods of treatment and uses.
The present invention is directed to a polypeptide for use in treating pain or an inflammatory disorder, wherein the polypeptide comprises a clostridial neurotoxin light-chain (L-chain), a clostridial neurotoxin translocation domain (HN domain) and/or a clostridial neurotoxin receptor binding domain (Hc domain), wherein when the polypeptide comprises a clostridial neurotoxin L-chain, the L-chain is catalytically inactive. Also provided are corresponding methods of treatment and uses.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
NCC domain), wherein when the polypeptide comprises a clostridial neurotoxin L-chain, the L-chain is catalytically inactive. Also provided are corresponding methods of treatment and uses.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
65.
CLOSTRIDIAL NEUROTOXINS COMPRISING AN EXOGENOUS ACTIVATION LOOP
The present invention relates to a method for proteolytically processing a single-chain clostridial neurotoxin into a corresponding di-chain clostridial neurotoxin, the method comprising: providing a single-chain clostridial neurotoxin; and contacting the single-chain clostridial neurotoxin with furin; wherein the single-chain clostridial neurotoxin has an activation loop comprising or consisting of the polypeptide sequence Arg-Xaa-Xaa-Arg; and wherein furin hydrolyses a peptide bond of the activation loop thereby producing a di-chain clostridial neurotoxin. The invention also relates to engineered clostridial neurotoxins and methods for manufacturing the same, as well as related pharmaceutical compositions, nucleotide sequences, and therapeutic and cosmetic uses.
A61K 8/64 - ProtéinesPeptidesLeurs dérivés ou produits de dégradation
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
66.
Genetically Engineered Cells Sensitive for Clostridial Neurotoxins
A cell that has been genetically engineered to be highly sensitive to clostridial neurotoxin, for example, botulinum neurotoxin and tetanus neurotoxin, or modified or recombinant versions thereof. A method for making such a genetically-engineered cell and a method for using such a cell in assaying the activity of modified or recombinant clostridial neurotoxin.
ccccinter aliainter alia) corresponding methods for producing the same, methods for selecting oxidation resistant clostridial neurotoxins, nucleic acids encoding the same, and therapeutic uses of said modified clostridial neurotoxins.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
The present invention provides a clostridial neurotoxin for use in a method of treating a brain disorder in a patient by promoting a neuroimmune response.
An engineered clostridial neurotoxin comprising an activation loop that comprises an amino acid sequence of the formula Cys-(Xaa)a-Ile-Asp/Glu-Gly-Arg-(Yaa)b-Cys, wherein a is an integer from 1 to 10, b is an integer from 4 to 15, each iteration of Xaa and Yaa individually represents an amino acid, and the engineered clostridial neurotoxin is not BoNT/C1, a method for producing the same, a method of treating a disease or condition comprising administering the engineered clostridial neurotoxin or the corresponding di-chain clostridial neurotoxin, a composition comprising the engineered clostridial neurotoxin or the corresponding di-chain clostridial neurotoxin, and a polynucleotide encoding the engineered clostridial neurotoxin. A method for proteolytically processing a single-chain clostridial neurotoxin into a corresponding di-chain clostridial neurotoxin, the method comprising contacting the single-chain clostridial neurotoxin with enterokinase or factor Xa and a di-chain clostridial neurotoxin produced using such a method. A method for hydrolyzing a peptide bond of a polypeptide comprising contacting the polypeptide with an enterokinase.
The present invention relates to a method for preparing a labelled polypeptide, the method comprising: a. providing a polypeptide comprising: i. a sortase acceptor site or a sortase donor site; ii. a non-cytotoxic protease or a proteolytically inactive mutant thereof; iii. a Targeting Moiety (TM) that is capable of binding to a Binding Site on a target cell; and iv. a translocation domain; b. incubating the polypeptide with: a sortase; and a labelled substrate comprising a sortase donor site or a sortase acceptor site, respectively, and a conjugated detectable label; wherein the sortase catalyses: conjugation between an amino acid of the sortase acceptor site of the polypeptide and an amino acid of the sortase donor site of the labelled substrate; or conjugation between an amino acid of the sortase acceptor site of the labelled substrate and an amino acid of the sortase donor site of the polypeptide; thereby labelling the polypeptide; and c. obtaining the labelled polypeptide. The invention also relates to polypeptides for labelling, labelled polypeptides, nucleic acids encoding said polypeptides, and methods of using and manufacturing said polypeptides.
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
A method for determining cleavage of a VAMP by a clostridial neurotoxin in a cell that has been contacted with the clostridial neurotoxin under conditions suitable for clostridial neurotoxin activity, the method comprising contacting the cytoplasmic content of the cell with an antibody that binds to a resulting C-terminal product of such cleavage under suitable conditions in vitro or ex vivo and detecting the binding of the antibody to the C-terminal cleavage product. The antibody may, for example, be capable of binding an antigenic polypeptide consisting of 10 to 65 amino acid residues and comprising an epitope comprising an amino acid sequence that is at least 90% identical to an amino acid sequence of at least 8 amino acid residues that is immediately C-terminal to a clostridial neurotoxin cleavage site in the VAMP.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A method for producing β-trypsin, the method comprising: a) renaturing denatured trypsinogen, thereby producing renatured trypsinogen, wherein the renaturing is carried out in a buffer that comprises L-arginine; b) purifying the renatured trypsinogen by anion 5 exchange chromatography, thereby providing purified renatured trypsinogen; and c) incubating the purified renatured trypsinogen under conditions to promote proteolytic activity of the trypsinogen, wherein trypsinogen is cleaved into β-trypsin by said proteolytic activity; wherein steps a) and b) are carried out under conditions that do not promote the proteolytic activity of trypsinogen; wherein the method does not comprise the addition of a further 10 protease for cleaving trypsinogen into β-trypsin; wherein at least step c) is carried out in a buffer that does not comprise L-arginine; and wherein prior to step c), when present in a buffer that does not comprise L-arginine, the trypsinogen is not subjected to a temperature of >8 °C for more than 38 hours.
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
74.
COLLECTING PHYSICAL THERAPY INFORMATION TO ENHANCE TREATMENT EFFICACY OF BOTULINUM TOXIN
Methods for improving active movement capacity in a subject experiencing muscle impaired or abnormal activity, and software products and computer systems for implementing such methods. A subject having impaired active movement capacity is administered an effective amount of botulinum toxin and instructed to undergo physical therapy, such as through a Guided Self-rehabilitation Contract (GSC), and to record information associated with the physical therapy into, e.g., a software program running on a computer device. The information may be stored in a database, which can be accessed by a medical practitioner who is administering the botulinum toxin. This information is used to improve the clinical management of the subject's impaired active movement capacity.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Method of treating or reducing a symptom of traumatic brain injury (TBI) in a subject, comprising administering to the subject a therapeutically-effective amount of botulinum neurotoxin. Composition for use in treating or reducing a symptom of TBI in a subject comprising botulinum neurotoxin. Computer system programmed to receive information related to a subject's response to administration of botulinum neurotoxin, store that response in a database, and transmit the response to a medical practitioner. Non-transitory computer-readable storage medium storing instructions that, when executed by a computer system, causes the computer system to perform the aforementioned steps.
There is provided a method of controlling operation of a fed batch process in a bioreactor vessel, comprising transitioning from a batch phase to a production phase in dependence on a relationship between an oxygen supply parameter O and a dissolved oxygen value DO.
C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
The present invention relates to a clostridial neurotoxin for use in treating post-operative surgical pain in a patient, said method comprising administering to a patient a clostridial neurotoxin more than 5 days prior to surgery and wherein the clostridial neurotoxin is administered: i) intradermally; or ii) intrathecally. Also provided are corresponding methods of treatment and administration dosages of a clostridial neurotoxin.
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
The present invention relates to a clostridial neurotoxin for use in treating post-operative surgical pain in a patient, said method comprising administering to a patient a clostridial neurotoxin more than 5 days prior to surgery and wherein the clostridial neurotoxin is administered: i) intradermally; or ii) intrathecally. Also provided are corresponding methods of treatment and administration dosages of a clostridial neurotoxin.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 29/02 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS] sans effet anti-inflammatoire
Mobile computing application for use in the determination of a recommended dose of a medicinal. Computer-implemented method for determining a dose for the administration of a medicinal to a subject wherein information is input by a user and the computer determines the total close for administration. Method for treating a disorder in a subject in need of such treatment, the method comprising using a computer-implemented method for determining a dose of the medicinal to be administered to the subject and administering such a dose to the subject.
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 40/67 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement à distance
80.
Therapeutic and Cosmetic Uses of Botulinum Neurotoxin Serotype E
The present invention is directed to a botulinum neurotoxin serotype E (BoNT/E) for use in treating a disorder, wherein the BoNT/E is administered to a human subject, and provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue in ≤13 days after administration; and reduces to >25% inhibition of neurotransmitter secretion from the target cell or tissue at day 14 after administration.
The present invention relates to a modified botulinum neurotoxin A (BoNT/A) for use in treating limb spasticity or paediatric limb spasticity, wherein the modified BoNT/A is administered by intramuscular injection to a plurality of affected muscles of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 53 Units to 948 Units or 26.5 Units to 474 Units of modified BoNT/A at the plurality of affected muscles.
The present invention relates to a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of Units to 41 Units of modified BoNT/A per site and wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines; and up to three sites at the external part of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 574 Units, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 15 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: i. substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; ii. substitution of an acidic surface exposed amino acid residue with an uncharged amino acid residue; iii. substitution of an uncharged surface exposed amino acid residue with a basic amino acid residue; iv. insertion of a basic amino acid residue; and v. deletion of an acidic surface exposed amino acid residue. Also provided are corresponding methods of treatment and uses, as well as unit dosage forms, and kits.
5050) in mice, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines; and up to three sites at the external part of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 574 Units, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 15 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: i. substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; ii. substitution of an acidic surface exposed amino acid residue with an uncharged amino acid residue; iii. substitution of an uncharged surface exposed amino acid residue with a basic amino acid residue; iv. insertion of a basic amino acid residue; and v. deletion of an acidic surface exposed amino acid residue. Also provided are corresponding methods of treatment and uses, as well as unit dosage forms, and kits.
The present invention relates to a modified botulinum neurotoxin A (BoNT/A) for use in treating limb spasticity or paediatric limb spasticity, wherein the modified BoNT/A is administered by intramuscular injection to a plurality of affected muscles of a subject, wherein the modified BoNT/A is administered by way of a unit dose of 53 Units to 948 Units or 26.5 Units to 474 Units of modified BoNT/A at the plurality of affected muscles.
The present invention relates to the treatment of skin conditions with neurotoxins, and non-therapeutic uses for cosmetic treatment of the skin. Administration of the neurotoxin induces secretion of one or more sebaceous lipid(s) selected from a squalene, a fatty acid, a cholesterol, and a wax ester to an epidermal layer of skin.
A61K 8/00 - Cosmétiques ou préparations similaires pour la toilette
A61K 8/99 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de micro-organismes autres que des algues ou des champignons, p. ex. à base de protozoaires ou de bactéries
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention relates to the treatment of skin conditions with neurotoxins, and non-therapeutic uses for cosmetic treatment of the skin. Administration of the neurotoxin induces secretion of one or more sebaceous lipid(s) selected from a squalene, a fatty acid, a cholesterol, and a wax ester to an epidermal layer of skin.
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Injection syringes, disposable hypodermic syringes for medical use, syringes for medical purposes and for injections. (1) Providing training in the use of injection syringes for the treatment of spasticity and cervical dystonia.
(2) Medical testing for diagnostic or treatment purposes; Providing medical information and advice on the treatment of spasticity and cervical dystonia.
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Injection syringes, disposable hypodermic syringes for medical use, syringes for medical purposes and for injections. (1) Providing training in the use of injection syringes for the treatment of spasticity and cervical dystonia.
(2) Medical testing for diagnostic or treatment purposes; Providing medical information and advice on the treatment of spasticity and cervical dystonia.
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Injection syringes, disposable hypodermic syringes for medical use, syringes for medical purposes and for injections. (1) Providing training in the use of injection syringes for the treatment of spasticity and cervical dystonia.
(2) Medical testing for diagnostic or treatment purposes; Providing medical information and advice on the treatment of spasticity and cervical dystonia.
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Injection syringes, disposable hypodermic syringes for medical use, syringes for medical purposes and for injections. (1) Providing training in the use of injection syringes for the treatment of spasticity and cervical dystonia.
(2) Medical testing for diagnostic or treatment purposes; Providing medical information and advice on the treatment of spasticity and cervical dystonia.
Method for suppressing bone cancer-induced allodynia in a patient, the method comprising administration of a therapeutically effective amount of a non-cytotoxic protease to a patient suffering from bone cancer.
A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; dietetic food
and substances adapted for medical or veterinary use, food
for babies; dietary supplements for humans and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides.
95.
C.L.I.M.B. HIGHER CONTINUUM OF LEARNING TO IMPROVE MANAGEMENT WITH BOTULINUM TOXIN
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Educational services, namely, congresses and workshops in the fields of healthcare, disease diagnosis, disease treatment and medical procedures; educational services, namely, online training in connection with healthcare, disease diagnosis, disease treatment, medical procedures, and training in the use of non-downloadable injection simulation software Medical information
The present technology relates to commercial-scale methods for purifying botulinum toxin compositions obtained from cell cultures. Purification methods according to the present disclosure are based on a series of filtration and chromatographic separation steps that produce a high-purity botulinum toxin composition, which comprises botulinum toxin protein molecules (~150 kDa) in solution, which is free, essentially free, or substantially free of botulinum toxin complexes and animal products, and without precipitating or lyophilizing botulinum toxin protein molecules. The purification method according to the present disclosure uses no precipitation, lyophilization, or centrifugation steps, permitting production of highly pure, highly active, free botulinum toxin protein molecules (~150 kDa) in solution, without the need for reconstitution by the end user.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
The present disclosure relates generally to the field of producing botulinum toxin. More specifically, the present disclosure relates to a method for producing botulinum toxin in a culture medium free or substantially free of animal product. The present disclosure also relates to the culture medium for producing botulinum toxin that is free or substantially free of animal product.
The present technology relates to commercial-scale methods for purifying botulinum toxin compositions obtained from cell cultures. Purification methods according to the present disclosure are based on a series of filtration and chromatographic separation steps that produce a high-purity botulinum toxin composition, which comprises botulinum toxin protein molecules (~150 kDa) in solution, which is free, essentially free, or substantially free of botulinum toxin complexes and animal products, and without precipitating or lyophilizing botulinum toxin protein molecules. The purification method according to the present disclosure uses no precipitation, lyophilization, or centrifugation steps, permitting production of highly pure, highly active, free botulinum toxin protein molecules (~150 kDa) in solution, without the need for reconstitution by the end user.
C07K 14/33 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Clostridium (G)
The present disclosure relates generally to the field of producing botulinum toxin. More specifically, the present disclosure relates to a method for producing botulinum toxin in a culture medium free or substantially free of animal product. The present disclosure also relates to the culture medium for producing botulinum toxin that is free or substantially free of animal product.
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Education and training services for healthcare professionals in the field of neurological diseases and muscular disorders. Providing medical information to healthcare professionals in the field of neurological diseases and muscular disorders.
